MA50418A - Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèse - Google Patents

Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèse

Info

Publication number
MA50418A
MA50418A MA050418A MA50418A MA50418A MA 50418 A MA50418 A MA 50418A MA 050418 A MA050418 A MA 050418A MA 50418 A MA50418 A MA 50418A MA 50418 A MA50418 A MA 50418A
Authority
MA
Morocco
Prior art keywords
synthesis
salts
methods
substituted heterocyclic
heterocyclic compounds
Prior art date
Application number
MA050418A
Other languages
English (en)
Inventor
John Emmerson Campbell
Kenneth William Duncan
James Edward John Mills
Michael John Munchhof
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of MA50418A publication Critical patent/MA50418A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
MA050418A 2017-10-18 2018-10-18 Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèse MA50418A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762573917P 2017-10-18 2017-10-18

Publications (1)

Publication Number Publication Date
MA50418A true MA50418A (fr) 2021-04-07

Family

ID=66173899

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050418A MA50418A (fr) 2017-10-18 2018-10-18 Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèse

Country Status (16)

Country Link
US (2) US20200247790A1 (fr)
EP (1) EP3697762A4 (fr)
JP (2) JP2021500334A (fr)
KR (1) KR20200101330A (fr)
CN (1) CN111417628A (fr)
AU (2) AU2018353122B2 (fr)
BR (1) BR112020007632A2 (fr)
CA (1) CA3079273A1 (fr)
CL (1) CL2020001009A1 (fr)
CO (1) CO2020005944A2 (fr)
EA (1) EA202090959A1 (fr)
IL (2) IL301746B2 (fr)
MA (1) MA50418A (fr)
MX (2) MX2020007152A (fr)
SG (1) SG11202003225YA (fr)
WO (1) WO2019079540A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102662065B1 (ko) 2017-02-17 2024-05-07 트레베나, 인코포레이티드. 7-원 아자-헤테로고리 함유 델타-오피오이드 수용체 조절 화합물, 및 그의 사용 및 제조 방법
CN118021814A (zh) 2017-04-21 2024-05-14 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
IL295978B2 (en) 2017-10-18 2024-01-01 Incyte Corp Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
CN114249785B (zh) * 2020-09-23 2024-04-05 常州方圆制药有限公司 一种2-腺苷n-吡唑的衍生物瑞加德松的制备方法
EP4236939A4 (fr) * 2020-10-27 2024-08-07 Trevena, Inc. Formes cristallines et amorphes d'un modulateur delta-opioïde
WO2025240956A1 (fr) * 2024-05-17 2025-11-20 Yale University Inhibiteur de g9a/ehmt2 utilisé pour le syndrome de prader-willi

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505858A (ja) * 2003-09-18 2007-03-15 ノバルティス アクチエンゲゼルシャフト 増殖性障害の処置に有用な２，４−ジ（フェニルアミノ）ピリミジン
NZ567851A (en) * 2005-11-01 2011-09-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US9284272B2 (en) * 2014-03-28 2016-03-15 Abbvie Inc. Inhibitors of histone methyltransferase G9a
DK3154957T3 (da) * 2014-06-16 2020-02-17 Fundacion Para La Investig Medica Aplicada Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser
EP3157524A4 (fr) * 2014-06-23 2017-12-06 Genentech, Inc. Méthodes de traitement du cancer et de prévention de la résistance aux médicaments anticancéreux
KR102571679B1 (ko) * 2016-04-15 2023-08-29 에피자임, 인코포레이티드 Ehmt1 및 ehmt2 저해제로서의 아민-치환된 아릴 또는 헤테로아릴 화합물
TWI808067B (zh) * 2016-12-19 2023-07-11 美商雅酶股份有限公司 作為ehmt2抑制劑之胺取代的雜環化合物及其使用方法
WO2018183923A1 (fr) * 2017-03-31 2018-10-04 Epizyme, Inc. Procédés d'utilisation d'inhibiteurs d'ehmt2
JP2021500327A (ja) * 2017-10-18 2021-01-07 エピザイム，インコーポレイティド 免疫療法にｅｈｍｔ２阻害剤を使用する方法

Also Published As

Publication number Publication date
CA3079273A1 (fr) 2019-04-25
EP3697762A1 (fr) 2020-08-26
US20200247790A1 (en) 2020-08-06
US20220324851A1 (en) 2022-10-13
CO2020005944A2 (es) 2020-07-31
IL301746B1 (en) 2024-09-01
IL273974A (en) 2020-05-31
IL273974B1 (en) 2023-04-01
BR112020007632A2 (pt) 2020-09-29
EP3697762A4 (fr) 2021-04-07
JP2023036991A (ja) 2023-03-14
MX2024012124A (es) 2025-02-10
AU2018353122A1 (en) 2020-06-04
WO2019079540A1 (fr) 2019-04-25
CL2020001009A1 (es) 2020-12-18
MX2020007152A (es) 2020-12-10
AU2024201165A1 (en) 2024-03-14
IL273974B2 (en) 2023-08-01
EA202090959A1 (ru) 2020-07-13
IL301746A (en) 2023-05-01
IL301746B2 (en) 2025-01-01
AU2018353122B2 (en) 2023-11-23
JP2021500334A (ja) 2021-01-07
KR20200101330A (ko) 2020-08-27
CN111417628A (zh) 2020-07-14
SG11202003225YA (en) 2020-05-28

Similar Documents

Publication Publication Date Title
MA47233A (fr) Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation
MA50418A (fr) Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèse
EP3402799A4 (fr) Composés hétérocycliques utilisés comme inhibiteurs du vrs
CY1124187T1 (el) Ετεροκυκλικα αμιδια ως αναστολεις κινασης
MA51846A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
EP3389783A4 (fr) Nouveaux composés utilisés comme inhibiteurs de l'indoléamine 2,3-dioxygénase
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA55633A (fr) Salicylamides de spiroheptane et composés associés utilisés comme inhibiteurs de rock
MA46045A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA45669A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MX378499B (es) Compuestos antifungicos.
MA44860A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA40301B1 (fr) Composés indolecarboxamides utiles comme inhibiteurs de kinase
EP3331880A4 (fr) Dérivés de n-(pyridin-2-yl)-4-(thiazol-5-yl) pyrimidin-2-amine utilisés comme composés thérapeutiques
MA46531A (fr) Dérivés d'azétidine ou de cyclobutane 1,3-disubstitués utilisés comme inhibiteurs de la prostaglandine d synthase hématopoïétique (h-pgds)
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
MA49374A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
MA50609A (fr) Énantiomères de thiazoles substitués utilisés comme composés antiviraux
EA201791684A1 (ru) Селективные ингибиторы bace1
MA51864A (fr) Méthodes d'identification de composés
EP3666770A4 (fr) Nouveaux composés hétérocycliques comme inhibiteurs de cdk8/19
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения
MA40250A (fr) Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
EP3710006A4 (fr) Composés hétéroaryle substitués et leurs méthodes d'utilisation